# In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma

> **NCT02811523** · PHASE1 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 17 (estimated)

## Conditions studied

- Bone Sarcoma
- Soft Tissue Sarcoma
- Pulmonary Metastases

## Interventions

- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT02811523
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-02
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811523, "In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02811523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*